Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

CVS Health

UnitedHealth Group

Humana slashed its Q4 earnings outlook on higher medical costs and warned about weak Medicare Advantage enrollment.

Humana Stock Falls Ill On This Warning; UNH, CVS Catch Virus

Humana Inc. shares HUM, +2.04% dropped 14% premarket on Thursday after the giant health insurer slashed its full-year 2023 earnings guidance and flagged rising medical costs and slower than expected 2024 Medicare Advantage enrollment growth.

Humana stock tumbles as Medicare Advantage growth disappoints

Humana expects fiscal 2023 adjusted earnings of about $26.09 a share, down from the company's prior estimates of $28.25.

Humana Stock Crumbles as Forecast Cut on Higher Medical Costs

Humana is the fifth-largest player in the healthcare plans industry with a market cap of $62 billion. Despite recent stock performance, Humana has outperformed the S&P 500 over the last ten and fifteen years. The company's strong growth in memberships and positive industry outlook make it a potentially solid Strong Buy investment opportunity.

Humana: My Oh My, Another Strong Buy

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Humana (HUM) is a Strong Growth Stock

Cigna

Elevance Health Inc

Incyte

Insulet

Health Care Select Sector SPDR Fund

Zoetis

Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.

Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024

Citigroup

If the economy were to start showing clear signs of weakening, defensive healthcare stocks such as UnitedHealth, Humana, and Cigna would look relatively attractive.

Healthcare Stocks Are Trying to Break Out. What They Need Now.

Walgreens

Walgreens Boots Alliance has agreed to pay $360 million to insurance company Humana to settle a lawsuit alleging the retail-pharmacy chain overcharged for prescription-drug reimbursements.

Walgreens to Pay Humana $360 Million to Settle Drug-Pricing Dispute

Why Humana (HUM) is a Top Value Stock for the Long-Term

Humana (HUM) closed the most recent trading day at $464.52, moving -1.19% from the previous trading session.

Humana (HUM) Registers a Bigger Fall Than the Market: Important Facts to Note

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the fourth quarter 2023 (4Q23) on Monday, February 5, 2024, at 6:30 a.m. Eastern time. The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2024. To participate via telephone, please register in advance using this link, https://register.vevent.com/register/BI4ed0098679fd435e8af0ab344fa47655. Upon reg.

Humana Inc. to Release Fourth Quarter 2023 Results on February 5, 2024

Given its attractive valuation, we believe that Humana stock (NYSE: HUM) is a better pick than its peer UnitedHealth Group stock (NYSE: UNH). Humana HUM stock trades at 0.6x trailing revenues versus 1.4x for UnitedHealth, partly due to the latter's superior profitability.

After An 11% Fall Last Year Is Humana A Better Pick Over UnitedHealth Stock?

Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.

Here's Why You Should Retain Humana (HUM) in Your Portfolio

As always, I am looking to improve the overall quality of my portfolio in 2024. Humana's total revenue and adjusted EPS grew at healthy clips in the third quarter. The company's interest coverage ratio was above 12 through the first three quarters of 2023.

Humana: Buy This Powerful Dividend Growth Stock In The New Year

Abbott Labs

McKesson

Finding investment opportunities in tune with today's demographic trends can be challenging, but aging population stocks may be the solution. This market is booming in a world with an aging population, creating a special opportunity for investors to profit.

Silver Economy Successes: 3 Stocks Benefitting From an Aging Population

The latest trading day saw Humana (HUM) settling at $453.94, representing a +0.45% change from its previous close.

Humana (HUM) Advances But Underperforms Market: Key Facts

Bio-Rad Laboratories

Bristol-Myers

Moderna

After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others.

6 Stock Picks in Healthcare for 2024

Centene

Molina Healthcare

Medical-HMO stocks like UNH, HUM, CNC and MOH are expected to reap the benefits of an aging U.S. population and growing premiums in 2024. However, challenges related to the resumption of elective procedures might play spoilsport.

4 Health Insurers Likely to Maintain Winning Streak in 2024

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Humana (HUM) is a Strong Value Stock

Humana (HUM) concluded the recent trading session at $461.46, signifying a -1.62% move from its prior day's close.

Humana (HUM) Falls More Steeply Than Broader Market: What Investors Need to Know

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading US health insurer and health care services company Humana Inc. (NYSE: HUM) has earned a score of 100 percent on the Human Rights Campaign Foundation Corporate Equality Index and the designation as one of the Best Places to Work for LGBTQ+ Equality for the tenth year in a row. The recognition reflects Humana's deep commitment to creating a culture of belonging where each employee feels valued and has both opportunity and support to reach their full poten.

Humana Earns Top Score in Human Rights Campaign Foundation's 2023 Corporate Equality Index

Eli Lilly

U.S. equities were little changed at midday ahead of key inflation data due later in the week and the final Federal Reserve policy meeting of 2023. The Dow and S&P 500 were up slightly, while the Nasdaq was in the red.

Midday Movers: Cigna Soars After Calling Off Humana Deal, Eli Lilly Falls Following Study

US health insurer Cigna (NYSE:CI) has abandoned plans to merge with Humana (NYSE:HUM), a transaction that would have created a $140 billion insurance giant, according to reports. The Financial Times said disagreement over financial arrangements, regulatory fears and falling share prices following reports of the potential tie-up drove Cigna's decision to halt plans, citing people with knowledge of the deal.

Cigna plans bumper buyback amid reports Humana merger talks end

Cigna (NYSE: CI ) has ditched its plans to acquire Humana (NYSE: HUM ), another huge health insurer. Instead, Cigna will buy back $10 billion of its own shares and carry out smaller M&A deals.

CI Stock Alert: Cigna Ditches Humana Acquisition for $10 Billion Stock Buyback

Cigna said it will consider smaller, "bolt-on" acquisitions in the near term, but did not confirm the reports about its abandoned pursuit of Humana.

News for Humana Stock (HUM)